“Executing an open innovation model: Cooperation is key . . .” Deloitte Report July 25, 2015 “Deloitte’s analysis of the current state of OI in biopharma reveals a higher success rate for OI pursuits than for closed-model product development. However, companies have sourced around 80 percent of their R&D pipeline via the more closed end of the OI spectrum. Adoption at the most open end is still infrequent and slow, mainly due to concerns about intellectual property (IP) rights, adopting new OI-based R&D models, and cultural and management style issues.”
